Karyopharm Therapeutics (KPTI) AI Stock Analysis

• Market Cap: $158.93M
• Dividend Yield: N/A
• Average Volume (3M): 228.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: -3.98%
• EPS Growth: -29.94%
• Country: US
• Employees: 279
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.82
• Shares Outstanding: 18,310,284
• 10 Day Avg. Volume: 494,784
• 30 Day Avg. Volume: 228,238
• PEG Ratio: 0.02
• Price to Book (P/B): -0.44
• Price to Sales (P/S): 0.57
• P/FCF Ratio: -0.65
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 1.24
• Enterprise Value/Gross Profit: 1.29
• Enterprise Value/Ebitda: -2.19
• 1Y Price Target: $14.00
• Price Target Upside: 71.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $8.50 ▲(4.04% Upside)

The score is held back primarily by weak financial performance (losses, negative equity, and deteriorating free cash flow). Technicals are supportive with strong trend momentum but appear overbought, and valuation offers limited support due to a negative P/E. Earnings call commentary improves the outlook somewhat via runway extension and upcoming clinical catalysts, but ongoing losses keep risk elevated.

Positive Factors

Product revenue growth

Sustained year-over-year product revenue growth demonstrates XPOVIO has durable commercial traction and product-market fit. Recurring sales provide a foundation for scaling commercialization, supporting reinvestment in the pipeline and partnerships that reinforce long-term revenue stability if execution continues.

Phase III enrollment complete

Finishing Phase III enrollment materially reduces execution risk and creates a clear, near-term structural catalyst. A positive SENTRY readout could enable label expansion into myelofibrosis, unlocking a multibillion-dollar market and permanently altering the company's growth trajectory and commercialization strategy.

High gross margins and cost cuts

Extremely high gross margins imply scalable product economics where incremental sales convert strongly to gross profit. Coupled with recent R&D and SG&A reductions and narrower expense guidance, this supports longer-term cash conservation and operational flexibility to weather trial periods and fund prioritized programs.

Negative Factors

Negative stockholders' equity

Negative equity indicates liabilities exceed assets, a structural solvency concern that constrains strategic options and increases refinancing risk. This impairs the company's ability to support large commercialization investments or endure adverse clinical outcomes without dilutive or costly financing.

Worsening free cash flow

Deepening negative free cash flow and reliance on external financing create an ongoing funding vulnerability. Limited cash runway into Q2 2026 forces near-term capital decisions that could dilute shareholders or raise borrowing costs, reducing strategic flexibility until durable revenue or trial-based milestones materialize.

Concentrated commercial risk

Heavy dependence on a single approved product concentrates downside risk: commercial performance and future growth hinge on XPOVIO uptake and successful trial readouts. In markets like myelofibrosis with limited recent innovation, failure to differentiate or expand indications would structurally limit revenue diversification.

Karyopharm Therapeutics Business Overview & Revenue Model

Company Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

How the Company Makes Money

Karyopharm Therapeutics generates revenue primarily through the commercialization of its lead product, Xpovio, which has received approval from regulatory authorities for treating certain types of cancers. The company earns money through direct product sales to healthcare providers and patients. In addition, Karyopharm may also generate revenue from collaborations and partnerships with other pharmaceutical companies, which could include licensing agreements, research and development collaborations, and milestone payments. These partnerships often enable Karyopharm to share the costs and risks associated with drug development while providing additional financial resources that contribute to the company's overall earnings.

Karyopharm Therapeutics Financial Statement Overview

Summary

Karyopharm Therapeutics faces significant financial challenges, including declining revenues, persistent losses, high leverage, and negative equity. The company's cash flow is insufficient, leading to reliance on external financing.

Income Statement

Karyopharm Therapeutics has experienced declining revenue over recent years, with a negative revenue growth rate of -0.55% from 2023 to 2024. The company also faces significant profitability challenges, as indicated by negative net profit margins and EBIT margins. Despite a relatively high gross profit margin of 95.87% in 2024, the persistent net losses highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt relative to assets suggests significant leverage. The equity ratio is negative, further emphasizing the financial instability and potential solvency risks.

Cash Flow

Karyopharm Therapeutics has negative free cash flow, which deteriorated by 37.66% from 2023 to 2024. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. Although there was a positive financing cash flow, it is insufficient to offset the negative operating cash flow, indicating reliance on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	142.53M	145.24M	146.03M	157.07M	209.82M	108.08M
Gross Profit	136.73M	139.23M	141.09M	151.86M	206.42M	105.38M
EBITDA	-80.42M	-38.60M	-118.42M	-139.31M	-96.98M	-167.85M
Net Income	-124.62M	-76.42M	-143.10M	-165.29M	-124.09M	-196.27M
Balance Sheet
Total Assets	96.23M	164.42M	240.44M	358.17M	305.31M	313.05M
Cash, Cash Equivalents and Short-Term Investments	45.88M	108.71M	191.44M	277.97M	228.62M	249.24M
Total Debt	196.42M	194.52M	177.02M	179.07M	180.58M	131.13M
Total Liabilities	365.49M	350.44M	376.64M	374.83M	384.98M	262.50M
Stockholders Equity	-269.26M	-186.02M	-136.21M	-16.66M	-79.67M	50.55M
Cash Flow
Free Cash Flow	-83.44M	-127.63M	-92.72M	-149.67M	-112.83M	-160.38M
Operating Cash Flow	-83.49M	-127.49M	-92.72M	-149.55M	-107.12M	-160.23M
Investing Cash Flow	48.37M	95.47M	7.94M	-104.26M	141.84M	-53.69M
Financing Cash Flow	1.04M	41.65M	1.12M	193.74M	73.65M	172.08M

Karyopharm Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTI, the sentiment is Positive. The current price of 8.17 is above the 20-day moving average (MA) of 7.29, above the 50-day MA of 6.37, and above the 200-day MA of 5.54, indicating a bullish trend. The MACD of 0.52 indicates Negative momentum. The RSI at 65.73 is Neutral, neither overbought nor oversold. The STOCH value of 76.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KPTI.

Karyopharm Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KPTI	53 Neutral	$158.93M	-0.56	―	―	-3.98%	-29.94%
LTRN	52 Neutral	$39.03M	-1.92	-104.58%	―	―	1.18%
IPSC	52 Neutral	$169.57M	-6.56	-14.23%	―	4121.12%	83.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BTAI	47 Neutral	$43.96M	-0.21	―	―	-66.96%	71.83%
ATNM	45 Neutral	$43.36M	-1.17	-133.09%	―	11.11%	20.65%
MDCX	43 Neutral	$38.93M	-0.69	-2237.54%	―	―	-55.95%

Karyopharm Therapeutics Corporate Events

Karyopharm Issues Preliminary 2025 Financial Results and Outlook

On January 12, 2026, Karyopharm reported preliminary unaudited financial results indicating it expects approximately $33 million in total revenue for the fourth quarter of 2025 and about $145 million for full-year 2025, including $32 million and $115 million, respectively, in U.S. XPOVIO net product revenue. The company ended 2025 with roughly $64 million in cash, cash equivalents, restricted cash and investments, and, along with anticipated product and license revenue, believes it can fund operations into the second quarter of 2026, supported by strategic financings that extended its cash runway beyond the upcoming Phase 3 SENTRY myelofibrosis readout. Operationally, Karyopharm completed enrollment of the Phase 3 SENTRY trial in myelofibrosis in September 2025, continued global expansion and steady demand for XPOVIO in a competitive multiple myeloma market, advanced Phase 2 and Phase 3 selinexor programs in myelofibrosis, and refined the design and enrollment of its Phase 3 XPORT-EC-042 endometrial cancer trial, setting up 2026 as a catalyst-heavy year with two major Phase 3 data readouts that could materially influence its position in oncology and long-term value for stakeholders.

The most recent analyst rating on (KPTI) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.

Karyopharm Therapeutics Completes Financing Transactions for Growth

On October 10, 2025, Karyopharm Therapeutics Inc. completed a series of financing transactions, including the issuance of convertible senior notes due in 2028 and 2029, and borrowed $12.5 million under its credit agreement. These transactions are aimed at strengthening the company’s financial position and supporting its strategic initiatives, potentially impacting its market standing and investor relations.

The most recent analyst rating on (KPTI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.